ClinicalTrials.Veeva

Menu

The TElemonitoring in the Management of Heart Failure (TEMA-HF) 1 Long-term Follow-up Study (TEMA-HFLT)

H

Hasselt University

Status

Completed

Conditions

Telemonitoring in Coronary Artery Disease

Treatments

Other: Telemonitoring

Study type

Interventional

Funder types

Other

Identifiers

NCT03171038
Jessa Hospital

Details and patient eligibility

About

TEMA-HF 1 Long-Term Follow-up study is a follow-up study of TEMA-HF 1. It assessed the long-term impact of a 6-months telemonitoring program in chronic heart failure patients.

Full description

The telemonitoring (TM) group patients received a 6-months TM program, followed by standard heart failure care until the long-term follow-up evaluation.

The usual care (UC) patients received ususal care during the first six months, followed by standard heart failure care until the long-term follow-up evaluation.

Enrollment

160 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Chronic heart failure patients
  • Treated for heart failure according to current guidelines
  • ≥ 18 years of age
  • Able to provide informed consent

Exclusion criteria

  • Reversible forms of acute heart failure (myocarditis)
  • Presence of severe aortic stenosis
  • Previous residency in a nursing home
  • Inclusion in a cardiac rehabilitation program on discharge
  • Chronic kidney disease stage ≥ 4
  • Planned dialysis in the next six months
  • Life expectancy < 1 year due to non-heart failure related reasons
  • Severe chronic obstructive pulmonary disease, GOLD ≥ III
  • Cognitive and/or mental problems interfering with the performance of daily measurements and data transmission

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

160 participants in 2 patient groups

Telemonitoring group
Experimental group
Description:
6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
Treatment:
Other: Telemonitoring
Usual care group
No Intervention group
Description:
Usual care from t0 up until the common stopping date (t2).

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems